Cory Kasimov
Stock Analyst at Evercore ISI Group
(4.33)
# 347
Out of 5,165 analysts
94
Total ratings
55.88%
Success rate
16.89%
Average return
Main Sectors:
Stocks Rated by Cory Kasimov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EWTX Edgewise Therapeutics | Maintains: Outperform | $30 → $45 | $29.78 | +51.11% | 3 | Feb 27, 2026 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $100 → $125 | $71.03 | +75.98% | 4 | Feb 25, 2026 | |
| ACLX Arcellx | Downgrades: In-Line | $115 | $114.51 | +0.43% | 2 | Feb 24, 2026 | |
| VIR Vir Biotechnology | Maintains: Outperform | $12 → $18 | $9.68 | +86.05% | 2 | Feb 24, 2026 | |
| MRNA Moderna | Maintains: In-Line | $28 → $35 | $53.31 | -34.35% | 7 | Feb 17, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $750 → $875 | $756.91 | +15.60% | 6 | Jan 22, 2026 | |
| IMNM Immunome | Maintains: Outperform | $18 → $40 | $20.36 | +96.46% | 2 | Dec 16, 2025 | |
| ZBIO Zenas BioPharma | Initiates: Outperform | $55 | $23.24 | +136.71% | 1 | Nov 26, 2025 | |
| BEAM Beam Therapeutics | Initiates: Outperform | $35 | $25.49 | +37.31% | 1 | Nov 24, 2025 | |
| ORIC ORIC Pharmaceuticals | Initiates: Outperform | $25 | $12.22 | +104.58% | 1 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $9.61 | +316.23% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $80 | $60.83 | +31.51% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $16.18 | +110.20% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $54.66 | +0.62% | 1 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $190 → $185 | $129.85 | +42.47% | 2 | Apr 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $110 → $125 | $90.54 | +38.06% | 4 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $115 → $105 | $57.43 | +82.83% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $84 → $88 | $21.82 | +303.30% | 6 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $324 → $276 | $183.26 | +50.61% | 4 | Dec 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $35 | $3.27 | +970.34% | 1 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $225 → $232 | $366.25 | -36.66% | 5 | Jul 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $93.00 | - | 5 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $145.21 | - | 5 | May 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $21 | $28.00 | -25.00% | 4 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $83 → $23 | $6.07 | +278.91% | 6 | Nov 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $15 → $10 | $1.61 | +521.12% | 1 | Feb 14, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $11.94 | - | 5 | Feb 14, 2018 |
Edgewise Therapeutics
Feb 27, 2026
Maintains: Outperform
Price Target: $30 → $45
Current: $29.78
Upside: +51.11%
BridgeBio Pharma
Feb 25, 2026
Maintains: Outperform
Price Target: $100 → $125
Current: $71.03
Upside: +75.98%
Arcellx
Feb 24, 2026
Downgrades: In-Line
Price Target: $115
Current: $114.51
Upside: +0.43%
Vir Biotechnology
Feb 24, 2026
Maintains: Outperform
Price Target: $12 → $18
Current: $9.68
Upside: +86.05%
Moderna
Feb 17, 2026
Maintains: In-Line
Price Target: $28 → $35
Current: $53.31
Upside: -34.35%
Regeneron Pharmaceuticals
Jan 22, 2026
Maintains: Outperform
Price Target: $750 → $875
Current: $756.91
Upside: +15.60%
Immunome
Dec 16, 2025
Maintains: Outperform
Price Target: $18 → $40
Current: $20.36
Upside: +96.46%
Zenas BioPharma
Nov 26, 2025
Initiates: Outperform
Price Target: $55
Current: $23.24
Upside: +136.71%
Beam Therapeutics
Nov 24, 2025
Initiates: Outperform
Price Target: $35
Current: $25.49
Upside: +37.31%
ORIC Pharmaceuticals
Nov 20, 2025
Initiates: Outperform
Price Target: $25
Current: $12.22
Upside: +104.58%
Nov 18, 2025
Initiates: Outperform
Price Target: $40
Current: $9.61
Upside: +316.23%
Sep 3, 2025
Maintains: Outperform
Price Target: $60 → $80
Current: $60.83
Upside: +31.51%
Aug 12, 2025
Maintains: Outperform
Price Target: $30 → $34
Current: $16.18
Upside: +110.20%
May 14, 2025
Initiates: Outperform
Price Target: $55
Current: $54.66
Upside: +0.62%
Apr 24, 2025
Maintains: Outperform
Price Target: $190 → $185
Current: $129.85
Upside: +42.47%
Nov 19, 2024
Upgrades: Outperform
Price Target: $110 → $125
Current: $90.54
Upside: +38.06%
Oct 30, 2024
Maintains: Outperform
Price Target: $115 → $105
Current: $57.43
Upside: +82.83%
Feb 27, 2024
Maintains: Overweight
Price Target: $84 → $88
Current: $21.82
Upside: +303.30%
Dec 21, 2021
Maintains: Neutral
Price Target: $324 → $276
Current: $183.26
Upside: +50.61%
Mar 1, 2021
Initiates: Neutral
Price Target: $35
Current: $3.27
Upside: +970.34%
Jul 29, 2020
Maintains: Neutral
Price Target: $225 → $232
Current: $366.25
Upside: -36.66%
May 6, 2020
Downgrades: Neutral
Price Target: n/a
Current: $93.00
Upside: -
May 1, 2020
Downgrades: Neutral
Price Target: n/a
Current: $145.21
Upside: -
Feb 14, 2020
Downgrades: Neutral
Price Target: $25 → $21
Current: $28.00
Upside: -25.00%
Nov 2, 2018
Maintains: Underweight
Price Target: $83 → $23
Current: $6.07
Upside: +278.91%
Feb 14, 2018
Maintains: Underweight
Price Target: $15 → $10
Current: $1.61
Upside: +521.12%
Feb 14, 2018
Downgrades: Underweight
Price Target: n/a
Current: $11.94
Upside: -